This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Background and Date of Approval
Pegylated Interferon Alpha-2B is an antineoplastic drug that belongs to the category of medicines known as interferons. It was approved by the U.S. FDA on June 27, 2001, to treat Chronic Hepatitis C.
Mechanism of Action of undefined
Pegylated Interferon Alpha-2B injection works by stimulating the body's immune system to fight off viral infections and cancer cells. Specifically, it activates certain immune cells, such as natural killer cells and T-cells, to attack and eliminate the infected virus or cancerous cells.
Uses of undefined
Pegylated Interferon Alpha-2B is indicated for the treatment of Chronic hepatitis C infection in patients above 18 years of age with compensated liver disease.
undefined Drug administaration and Dosage available
Pegylated Interferon Alpha-2B injection is administered as a subcutaneous injection (under your skin). If this drug is recommended for you, it will be given by a doctor. Do not self-administer. The recommended dose is 1.5 micrograms/kg/week. Your doctor will choose the dosage and administration frequency based on the condition because it differs from person to person.
Warnings, Precautions and Side Effects of undefined
This Pegylated Interferon Alpha-2B is contraindicated in patients who have hypersensitivity reactions. This medicine may cause allergic reactions in some people. Symptoms of an allergic reaction include itching, difficulty breathing, swelling of the face or throat, and a rapid heartbeat. If you experience any of these symptoms, consult your doctor immediately. This medicine should not be used in patients with decompensated liver disease. It is a serious condition where the liver is severely damaged and is no longer able to function properly, so it is highly advised to avoid taking this medicine.
This medicine should be used with caution in patients with creatinine clearance below 50 mL/min, as this indicates moderate to severe impairment of renal function. This can lead to slower clearance of the medication, which may increase the risk of toxicity and adverse effects. The dosage of Pegylated Interferon Alpha-2B should be reduced in these patients, and they should be closely monitored for signs of toxicity, such as fatigue, depression, or decreased white blood cell count. Therefore, the dose should be adjusted accordingly in patients with renal impairment. Tell your healthcare provider before beginning this treatment if you are pregnant or planning to have a baby. As this drug may cause harm to an unborn baby, it is advised for both men and women to follow proper contraceptive methods during and one week after the last dose of Pegylated Interferon Alpha-2B. Avoid breastfeeding your baby while you are on the treatment, as this drug can impact the growth and development of the baby by passing into the breast milk.
The common side effects of Pegylated Interferon Alpha-2B are headache, hair loss, muscle pain, insomnia, eye irritation, weight loss and loss of appetite. Other serious side effects include low or high BP, increased heart rate and depression. Inform your physician if you face any of the symptoms.
Word Of Advice
Pegylated Interferon Alpha-2B can make you feel dizzy and weak. Avoid driving or operating heavy machines if you experience dizziness, confusion, or tiredness while on treatment with this drug. This drug may affect liver function and blood cell counts, and regular monitoring is necessary to ensure that the medication is not causing any harm. This medicine can reduce the body's immune response, which may increase the risk of infection. Therefore, it is important to avoid contact with people who are sick and it is advised to practice good hand hygiene. It is advised to keep the injection out of reach of children and pets. If medication is no longer needed or has expired, it should be disposed of properly and not kept in the household trash.
Frequently Asked Question
- Biocon, [Revised on Aug 2015] [Accessed on 26th Jul 2021], https://www.biocon.com/docs/prescribing_information/virology/CimiPeg_PI_v1.pdf
- Schering Corporation, US Food & Drug Administration, [Revised on 26th Sep 2003] [Accessed on 26th Jul 2021], https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/pegsche080701lb.htm
- Q.M. Anstee, D.E.J. Jones, Liver and biliary tract disease, Davidson's Principles and Practice of Medicine, 22nd Edition, 2014, 921-988.
- KD Tripathi, Antiviral Drugs (Anti-retrovirus), Essentials of Medical Pharmacology, 8th Edition, 2019, 860-872.
The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.